Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - Barclays initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with an Overweight rating and a price target of $125.00 on Monday. The $633 million market cap company has seen remarkable growth, with shares surging nearly 300% year-to-date and an impressive 1,497% over the past year, according to InvestingPro data.
The research firm highlighted MNPR’s lead asset ALXN1840, an investigational therapy for Wilson disease, which Barclays believes supports approval and potential peak sales of approximately $1 billion. The strong analyst consensus, with multiple earnings forecast upgrades, reflects growing confidence in the company’s pipeline potential.
Barclays values ALXN1840 at $169 per share when fully de-risked, noting that Monopar is preparing to submit a New Drug Application to the FDA in early 2026, potentially leading to approval in late 2026 or early 2027.
The firm also mentioned Monopar’s radiopharmaceutical platform as providing potential longer-term growth opportunities, with lead assets MNPR-101-Zr and MNPR-101-Lu currently in a Phase 1a study in Australia.
Barclays indicated it does not yet ascribe value to the radiopharmaceutical platform in its current valuation model for the company.
In other recent news, Monopar Therapeutics has seen a series of positive developments. Jones Trading initiated coverage on Monopar with a Buy rating, emphasizing the potential of their Wilson’s Disease treatment, ALXN1840, which was acquired in October 2024. Raymond James raised its price target for Monopar to $142 from $80, maintaining a Strong Buy rating, following a letter in the Journal of Hepatology that corrected previous copper balance data for ALXN1840. Similarly, H.C. Wainwright increased its price target to $105 from $70, also maintaining a Buy rating, after a peer-reviewed letter challenged previous conclusions about the drug’s effectiveness. Piper Sandler adjusted its price target to $95 from $76, maintaining an Overweight rating, after Monopar announced a new analysis of the Phase 2 ALXN1840-WD-204 study. BTIG also raised its price target to $104 from $87, maintaining a Buy rating, following an updated analysis published in the Journal of Hepatology. These developments reflect a growing confidence among analysts in Monopar’s potential within the Wilson’s Disease treatment market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.